Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 48(5); 2024 > Article
Letter
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
Eun Young Leeorcidcorresp_icon
Diabetes & Metabolism Journal 2024;48(5):1005-1007.
DOI: https://doi.org/10.4093/dmj.2024.0417
Published online: September 12, 2024
  • 491 Views
  • 41 Download

Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

corresp_icon Corresponding author: Eun Young Lee orcid Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea E-mail: leyme@catholic.ac.kr

Copyright © 2024 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
See the reply "Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)" in Volume 48 on page 1012.
See the article "Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients" on page 253.
Diabetes mellitus is a major public health concern that affects millions of people worldwide [1]. It can lead to various issues if not properly managed, including both macrovascular and microvascular complications [2]. The growing prevalence of diabetes underscores the need for effective treatment strategies to manage this chronic disease. Effective blood glucose control is directly linked to the reduction of risks associated with diabetes. The UK Prospective Diabetes Study is a landmark study that demonstrated that early treatment to lower glycemia using metformin was associated with reductions in myocardial infarction, diabetes-related death, and all-cause mortality, with continued benefits observed after 10 years [3]. These findings highlight the importance of maintaining early glycemic control to reduce the long-term risks associated with diabetes.
However, in clinical practice, a stepwise approach to diabetes treatment often leads to clinical inertia [4], where delays in intensifying therapy occur despite suboptimal blood glucose control. This can result in prolonged periods of poor glycemic control, increasing the risk of complications. Early combination therapy, which involves using multiple medications from the start, could be more effective for achieving and maintaining glycemic targets, thereby reducing the risk of complications. The Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes (VERIFY) trial is a notable study that demonstrated the effectiveness of early combination therapy for managing diabetes [5]. This trial provided evidence that starting treatment with a combination of medications early in the disease course leads to better long-term glycemic control compared to initial metformin monotherapy for patients with newly-diagnosed type 2 diabetes mellitus (T2DM). The results indicate the importance of considering early combination therapy for optimal diabetes management.
In addition to initial combination therapy, several recent studies have explored the efficacy and safety of initial triple combination therapy for diabetes management [6-8]. In this article, entitled “Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients,” Park et al. [6] investigated the effectiveness and safety of an initial triple therapy regimen for managing T2DM in drug-naïve patients. They demonstrated that initial triple therapy with metformin, sitagliptin, and empagliflozin significantly reduced glycosylated hemoglobin (HbA1c) levels and improved metabolic function and albuminuria over 24 months in drug-naïve T2DM patients, achieving and maintaining glycemic targets without severe hypoglycemia or serious adverse events. This study was well-structured, following a prospective, observational approach that spanned 2 years. The inclusion criteria were clear, focusing on drug-naïve patients with newly-diagnosed T2DM, which ensured a specific and relevant patient population. This study revealed significant improvement in glycemic control, with a substantial reduction in HbA1c levels from 11.0%±1.8% at baseline to 7.0%±1.7% at 24 months. The rates of achieving target HbA1c levels (<7.0%) were impressive, with 72.5% at 12 months and 61.7% at 24 months. This highlights the potential of initial triple therapy to achieve and maintain glycemic targets more effectively than traditional stepwise approaches. It is intriguing that both insulin sensitivity and β-cell function improved with initial triple therapy, as well as metabolic profiles and albuminuria. Remarkably, the improvement in insulin sensitivity and β-cell function appeared early in the study period (2 months) and was sustained during follow-up (24 months). Furthermore, the study reported a favorable safety profile for triple therapy.
However, it should be noted that for patients whose blood glucose levels are not controlled and who exhibit hyperglycemic symptoms such as weight loss, polydipsia, and polyuria, insulin therapy should be considered a priority [9]. Although the authors stated that patients with symptoms of hyperglycemia were excluded from the study, the average HbA1c level of the study participants at the start was 11.0%. They also mentioned that temporary increases in blood glucose levels during the study were managed with insulin therapy for safety reasons, but they did not report how many patients received insulin treatment. Considering that 48.2% of patients were hospitalized at the beginning of the study, it is possible that short-term insulin therapy or strict dietary control was also implemented. Additionally, it should be confirmed that insulin secretion ability has not significantly declined before considering triple oral therapy. Furthermore, as the authors also noted, while the study demonstrates the effectiveness of triple therapy, it lacks a comparative arm with traditional sequential therapy or other combination therapies. Including a control group with a different treatment regimen would have provided more context for evaluating the relative efficacy and safety of triple combination therapy. Potential bias in subgroup analysis cannot be excluded. The decision to adjust medication regimens after 12 months based on physician judgment introduces potential bias. Subgroup analysis, which compared patients who continued triple therapy with those who reduced to two medications, may also reflect inherent biases related to the physicians’ discretion rather than the efficacy of the treatment protocols. More standardized criteria for these adjustments would have strengthened the study’s conclusions. Lastly, one major limitation is the study’s generalizability. The patient cohort consists exclusively of Korean patients from a single hospital, which may not represent the broader global population with T2DM. Ethnic and genetic differences can influence drug efficacy and safety, and thus the findings may not be directly applicable to other populations without further validation.
I hope that further large prospective studies will reveal the efficacy and safety of initial triple combination therapy, comparing various regimes as well as using a stepwise approach in multiple ethnic groups, which would confirm these findings and broaden their applicability.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

  • 1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119.ArticlePubMed
  • 2. Gedebjerg A, Almdal TP, Berencsi K, Rungby J, Nielsen JS, Witte DR, et al. Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: a cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications 2018;32:34-40.ArticlePubMed
  • 3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.ArticlePubMed
  • 4. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 2013;36:3411-7.PubMedPMC
  • 5. Matthews DR, Paldanius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519-29.ArticlePubMed
  • 6. Park YH, Sohn M, Lee SY, Lim S. Two-year therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and empagliflozin in drug-naïve type 2 diabetes mellitus patients. Diabetes Metab J 2024;48:253-64.PubMedPMC
  • 7. Lim S, Ku EJ, Lee SY, Lee JH, Lee JE, Kim KM, et al. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study. BMJ Open Diabetes Res Care 2020;8:e000807.ArticlePubMedPMC
  • 8. Abdul-Ghani MA, Puckett C, Triplitt C, Maggs D, Adams J, Cersosimo E, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-75.PubMedPMC
  • 9. Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, et al. 2023 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J 2023;47:575-94.PubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
        Diabetes Metab J. 2024;48(5):1005-1007.   Published online September 12, 2024
        Close
      • XML DownloadXML Download
      Related articles
      Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
      Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64)
      Lee EY. Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64). Diabetes Metab J. 2024;48(5):1005-1007.
      DOI: https://doi.org/10.4093/dmj.2024.0417.

      Diabetes Metab J : Diabetes & Metabolism Journal
      Close layer
      TOP